TERNS PHARMACEUTICALS INC's ticker is TERN and the CUSIP is 880881107. A total of 94 filers reported holding TERNS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $107,577 | -40.4% | 21,387 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $180,486 | +802.4% | 20,627 | +202.8% | 0.00% | – |
| Q1 2022 | $20,000 | -61.5% | 6,811 | -6.6% | 0.00% | – |
| Q4 2021 | $52,000 | -33.3% | 7,289 | -2.9% | 0.00% | – |
| Q3 2021 | $78,000 | +30.0% | 7,507 | +53.7% | 0.00% | – |
| Q2 2021 | $60,000 | -46.4% | 4,883 | -3.8% | 0.00% | – |
| Q1 2021 | $112,000 | – | 5,075 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 6,657,992 | $33,489,700 | 3.67% |
| ACUTA CAPITAL PARTNERS, LLC | 555,260 | $2,792,958 | 1.87% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 6,041,910 | $30,390,807 | 1.64% |
| VR Adviser, LLC | 3,092,273 | $15,554,133 | 1.64% |
| Fairmount Funds Management LLC | 2,040,000 | $10,261,200 | 1.24% |
| Decheng Capital Management III (Cayman), LLC | 714,285 | $3,592,854 | 1.20% |
| Deep Track Capital, LP | 6,000,000 | $30,180,000 | 1.16% |
| Orbimed Advisors | 7,619,135 | $38,324,249 | 0.81% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 500,000 | $2,515,000 | 0.76% |
| GREAT POINT PARTNERS LLC | 645,899 | $3,248,872 | 0.59% |